FDA Greenlights uniQure’s AMT-130 Data for Accelerated Approval Filing
uniQure's stock surged after the FDA indicated that three-year Phase I/II data for its Huntington's disease gene therapy, AMT-130, could support an...

uniQure's stock surged after the FDA indicated that three-year Phase I/II data for its Huntington's disease gene therapy, AMT-130, could support an...

Biogen Inc. announced an agreement to acquire private biotech RayThera Inc. for up to $1 billion, significantly expanding its immunology portfolio with...

Major transactions and discussions marked the week, with GSK, Incyte, Ingredion, and OpenAI among the notable players. Roku's potential sale also generated...

Apotex Health Corp. and its backers secured C$1.3 billion ($932 million) in a Toronto IPO, pricing shares at the top end of...

Eli Lilly's experimental obesity drug retatrutide delivered positive late-stage trial results, showing substantial weight loss and improvements in type 2 diabetes, knee...

As investors rotate out of technology, three dividend-growth stocks—AbbVie, Procter & Gamble, and Enterprise Products Partners—offer stability and attractive yields for a...

NervGen Pharma Corp. has priced a public offering of common shares and warrants, raising $60 million to advance its neuroreparative therapeutics.

Ars Pharmaceuticals is expanding its $199 neffy retail access program while awaiting a crucial decision from CVS Caremark, aiming to boost affordability...

Retirees seeking income can find compelling opportunities in the healthcare sector. Three dividend-paying stocks—Pfizer, Medtronic, and Omega Healthcare—offer yields up to 6.5%...